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Objectives This study sought to investigate the blood pressure (BP) response after transcatheter
aortic valve implantation (TAVI) and its correlation with short- and mid-term clinical outcomes.
Background TAVI is an emerging therapy for aortic stenosis patients at high surgical risk. The acute
hemodynamic sequelae of this procedure and their clinical relevance are yet unclear.
Methods Consecutive patients who underwent TAVI in a single center were prospectively moni-
tored for BP response during 5 post-procedural days. Clinical parameters, adverse events, and medi-
cal treatment were recorded during hospitalization, at 30 days, and at 12 months after the proce-
dure. Patients were divided according to their post-procedural BP response into 2 groups: increased
BP and stable BP.
Results One hundred and ﬁve patients were analyzed. Overall, systolic BP increased immedi-
ately after TAVI in the entire cohort by an average of 15  31 mm Hg. This rise was sustained
and led to intensiﬁcation of antihypertensive treatment in 53 patients (51%); these patients
were designated as the increased BP group. The increase in systolic BP after TAVI was associ-
ated with an increase in stroke volume and cardiac output and was not related to age, baseline
cardiac function, or procedural outcomes. Patients with increased BP after TAVI had a signiﬁ-
cantly better prognosis with fewer adverse events in the hospital (21% vs. 62%, p  0.01), after
0 days (30% vs. 71%, p  0.01), and after 12 months (53% vs. 83%, p  0.01) as compared
ith patients with stable BP.
onclusions After TAVI, a substantial number of patients have a signiﬁcant rise in systolic BP neces-
itating long-term treatment. This increase in BP is associated with an increase in cardiac output and
redicts a better clinical outcome. (J Am Coll Cardiol Intv 2013;6:472–8) © 2013 by the American
ollege of Cardiology Foundation
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473Severe aortic stenosis (AS) often presents with normal
arterial systolic blood pressure (BP) in lieu of elevated
intraventricular systolic pressure and, consequently, a pres-
sure gradient across the aortic valve. Pre-procedural hyper-
tension (HTN) is a risk factor and a predictor of increased
mortality after aortic valve replacement (AVR) (1). Remod-
eling and reduction of left ventricular (LV) hypertrophy
after AVR appear to correlate with a favorable clinical
outcome (2). The disappearance of the pressure gradient
across the aortic valve following surgical AVR often leads to
dramatic hemodynamic changes and increased hypertension
(3,4) that can challenge the post-procedural care and may
further affect these patients in the chronic phase. The use of
antihypertensive medications after surgery has been shown
to improve LV remodeling in these patients (5,6).
Transcatheter aortic valve implantation (TAVI) is a novel
approach for the treatment of severe AS patients who are
inoperable or at high surgical risk. Unlike surgical AVR,
TAVI is often performed under local anesthesia (7), and the
post-procedural care takes place mainly in cardiac intensive
care units. Studies that assessed the post-procedural hemo-
dynamic sequelae of TAVI have focused on complications
and hypotension rather than on the hypertensive response
(7,8). Gotzmann et al. (9) described a rise in systolic BP
immediately after TAVI, not related to a change in ejection
fraction. Nevertheless, the causes, persistence, and clinical
significance of this response are yet unclear. In this study, we
prospectively investigated the in-hospital hemodynamic
changes post-TAVI and their clinical correlations during 12
months of follow-up.
Methods
Study population and post-procedural monitoring. Con-
ecutive patients who underwent TAVI at our institution
ere prospectively analyzed. All patients had severe symp-
omatic AS diagnosed clinically and confirmed by Doppler
chocardiography. The study subjects were declined for
urgery and referred to TAVI due to an increased surgical
isk as assessed by an institutional heart team.
After TAVI, patients were transferred to the cardiac
ntensive care unit with continuous BP monitoring imme-
iately after the procedure and during the following 5 days.
he highest BP measurement was recorded every 8 h and
sed for analysis. Patients were initially kept on their
re-procedural antihypertensive therapy. Uncontrolled BP
as promptly treated; treatment decisions were not re-
tricted and were decided by the treating physicians. Base-
ine BP levels were measured in the pre-admission office
isit.
All patients had echocardiograms performed after TAVI.
ost-procedural aortic regurgitation was graded on a scale of
to 4 according to vena contracta width, jet diameter to left
entricular outflow tract (LVOT) diameter ratio and cir-umferential extent in the short-axis view. Valve areas,
ressure gradients, stroke volume, and cardiac output were
alculated using LVOT Doppler waveforms, LVOT diam-
ter, heart rate, and the continuity equation as per standard
echniques (10–12). Arterial compliance was calculated as
troke volume/pulse pressure (ml/mm Hg) (13). Procedural
omplications were recorded according to the Valve Aca-
emic Research Consortium definitions (14).
BP response after TAVI. Patients were divided into 2 groups
ccording to the presence or absence of an increase in BP
fter TAVI.
Increased BP after TAVI was defined in the presence of
ne of the following:
1. A sustained (48 h) systolic pressure140 mmHg or
diastolic pressure 90 mm Hg that was not present at
baseline, before TAVI.
2. A need to increase more than 2-fold the dosage of an
antihypertensive drug to achieve control of systemic BP.
3. A need to add an additional antihypertensive medicine
to the pre-procedural regi-
men in order to achieve
control of systemic BP.
Endpoints. Clinical outcomes
were recorded during hospital-
ization, at 30 days, and at 12
months after the procedure. Se-
rious adverse events recorded
during follow-up included:
worsening heart failure; myocar-
dial infarction; stroke; and re-
current hospitalization due to
any cause and death.
Statistical analysis. Comparison
f quantitative variables was performed using an unpaired
tudent t test whereas Fisher exact test was used to compare
ualitative variables. Survival analysis was obtained by
aplan-Meier estimates. Differences among the groups
ere compared with the log-rank test. All data were initially
ntered into a commercially available statistical program
PSS (version 17.0 for Windows, SPSS Inc., Chicago,
llinois).
esults
Study population. One hundred and five consecutive pa-
tients were included in the study. Mean age was 80.7  6.6
years and logistic EuroSCORE (European System for
Cardiac Operative Risk Evaluation) was 23.3  15.1. The
baseline characteristics of the patients according to post-
TAVI BP response are presented in Table 1. The 2 groups
were similar in age, prevalence of HTN, logistic Euro-
SCORE, systolic and diastolic BP, ejection fraction, cardiac
Abbreviations
and Acronyms
AS  aortic stenosis
AVR  aortic valve
replacement
BP  blood pressure
HTN  hypertension
LV  left ventricle
LVOT  left ventricular
outflow tract
TAVI  transcatheter aortic
valve implantationoutput, cardiac index, and aortic valve parameters. However,
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474patients with increased BP were thinner (body mass index:
26.5 vs. 28.6 kg/m2, p  0.05) and were using significantly
ess antihypertensive medications to achieve a similarly
ell-controlled BP at baseline before TAVI.
The 2 groups had similar systemic vascular resistance and
rterial compliance at baseline. In accordance with the
lderly age of our cohort and the high prevalence of HTN,
rterial compliance was low in both groups (1.11  0.47
l/mm Hg vs. 1.26  0.45 ml/mm Hg, p  0.11).
There was no difference in the use of general anesthesia
etween the groups, nor the use of different approaches for
alve delivery (transfemoral, trans-subclavian, and direct
ortic). There was no difference between patients implanted
ith Medtronic CoreValve (Minneapolis, Minnesota) or
dwards Sapien XT valves (Edwards Lifesciences, Irvine,
alifornia) (Table 2).
Hemodynamic response. Eighty-five patients (81%) had a
prior diagnosis of HTN, and 16 additional patients (15%)
were treated with antihypertensive medications for other
diagnoses (e.g., heart failure and ischemic heart disease).
Systolic BP rose immediately after TAVI in the entire
cohort by an average of 15 mm Hg (31) and remained 8
mm Hg above baseline 5 days after the procedure despite
medical treatment (p  0.01 for both changes) (Fig. 1).
Diastolic BP following TAVI was significantly reduced imme-
diately after TAVI, and the diastolic BP was 7 mm Hg lower
than baseline after 5 days (p  0.01 for both changes).
Fifty-three patients (51%) had increased BP after TAVI
and constituted the increased BP group. They all required
intensification of antihypertensive therapy, including 27
patients in which parenteral BP lowering drugs were ad-
ministered. In fact, 9 patients in this group (17%) had not
been previously diagnosed as hypertensive. In the increased
BP group, the number of antihypertensive drugs rose
Table 1. Baseline Characteristics According to BP Response After TAVI
Variable
Increased BP
(n  53)
Stable BP
(n  52) p Value
Age, yrs 81 6 80 7 0.46
Male 25 (47) 25 (48) 1.0
BMI, kg/m2 26.5 4.2 28.8 5.9 0.04
Logistic EuroSCORE 23.5 15.3 23.2 14.9 0.91
Ejection fraction, % 54.8 11.7 56.8 12.0 0.39
HTN 44 (83) 41 (79) 0.63
Number of anti-HTN drugs 2.47 1.23 3.21 1.67 0.01
Coronary artery disease 30 (57) 28 (54) 0.84
Previous CABG 15 (28) 11 (21) 0.49
NYHA score 3.15 0.36 3.17 0.51 0.81
Chronic renal failure 6 (11) 7 (13) 0.77
Diabetes 17 (32) 20 (38) 0.54
Values are mean SD or n (%).
BMIbodymass index; BPbloodpressure; CABG coronary artery bypass graft; EuroSCORE
European System for Cardiac Operative Risk Evaluation; HTN hypertension; NYHANew YorkHeart Association; TAVI transcatheter aortic valve implantation.significantly by an average of 0.83  1.03, whereas in the
group of patients with stable BP after TAVI, the number of
drugs decreased on average by 1.02  1.30 (p  0.01 for
both changes).
Cardiac output, cardiac index, and stroke volume after
TAVI were significantly increased in patients with increased
BP versus patients with stable BP (p  0.05). Patients with
stable BP had, on average, a small reduction in stroke
volumes and cardiac outputs (Table 3).
Elevated BP after TAVI was not associated with
baseline arterial compliance, which was similar in both
Table 2. Procedure Technique and Related Complications in Both Groups
Variable
Increased BP
(n  53)
Stable BP
(n  52) p Value
Approach
Transfemoral 46 (87) 43 (82) 0.59
Trans-subclavian 6 (11) 5 (10) 1.0
Direct aortic 1 (2) 4 (8) 0.20
Medtronic CoreValve/Edwards Sapien XT 46/7 43/9 0.59
General anesthesia 34 (64) 29 (56) 0.43
Periprocedural death 0 (0) 1 (2) 0.49
Tamponade 2 (4) 3 (6) 0.67
Major bleeding* 29 (55) 22 (42) 0.24
Major vascular complications* 5 (9) 3 (6) 0.71
Acute kidney injury, any grade* 8 (15) 9 (17) 0.79
Severe infection 6 (11) 5 (10) 1.0
Pacemaker implantation† 22 (41) 13 (25) 0.09
Values are n or n (%). *By VARC definitions. †Pacemaker implanted due to advanced conduction
blocks.
BP blood pressure; VARC Valve Academic Research Consortium.
Figure 1. Average BP Response After TAVI in the Entire Cohort
Systolic blood pressure (BP) rose immediately after transcatheter aortic
valve implantation (TAVI) and remained signiﬁcantly higher than baseline
BP despite medical treatment. Diastolic BP decreased signiﬁcantly immedi-
ately after TAVI and remained lower at day 5 than at baseline.   p 
0.01 for difference with baseline.
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475groups (Table 3). Systemic vascular resistance was largely
unchanged after valve implantation with no association to
BP response (Table 3).
Clinical outcomes. There were 4 in-hospital deaths (3.8%),
5 deaths at 30 days (4.7%), and 13 deaths at 12 months
(12.3%) (Fig. 2, Table 4). There was a trend toward more
in-hospital deaths in patients with stable BP (0% vs. 8%,
p  0.056), but no significant differences in survival were
seen after 12 months of follow-up.
The rates of in-hospital, 30 day, and 12-month serious
adverse events were 21%, 30%, and 53%, respectively, for
patients with increased BP as compared to 60%, 71%, and 83%
for patients with stable BP (p 0.01 for all differences between
groups) (Fig. 3, Table 4). The majority of these events were
episodes of worsening heart failure (Fig. 4), which were less
frequent in the increased BP group than in the stable BP
group (17% vs. 54% in-hospital, p  0.01, and 23% vs. 60%
at 12 months, p  0.01). Adverse events possibly related to
increased HTN such as stroke or transient ischemic attack,
myocardial infarction, and acute kidney injury were rare and
similar between the 2 groups. The adverse events reported
Table 3. Hemodynamic and Echocardiographic Characteristics According
to BP Response Before and After TAVI
Variable
Increased BP
(n  53)
Stable BP
(n  52) p Value
Baseline data
Systolic BP, mm Hg 128.6 18.0 124.6 17.1 0.25
Diastolic BP, mm Hg 68.0 11.6 68.6 10.0 0.78
Pulse pressure, mm Hg 60.6 14.8 56.0 17.2 0.15
Aortic valve area, cm2 0.65 0.18 0.66 0.17 0.77
Maximal gradient, mm Hg 74.8 19.8 69.2 22.2 0.18
Mean gradient, mm Hg 46.2 13.4 43.3 14.7 0.29
Arterial compliance, ml/mm Hg 1.11 0.47 1.26 0.45 0.11
Systemic vascular resistance, dyne/cm 1,702 606 1,562 460 0.2
Cardiac output, l/min 4.3 1.2 4.5 1.4 0.43
Cardiac index, l/min 2.4 0.7 2.5 0.8 0.56
Stroke volume, ml 64 19 68 21 0.33
Post-procedural data
Systolic BP immediately after TAVI,
mm Hg
154.9 29.9 126.1 24.4 0.01
Diastolic BP immediately after TAVI,
mm Hg
64.3 14.1 59.6 16.3 0.17
Pulse pressure immediately after
TAVI, mm Hg
90.6 24.7 66.6 19.9 0.01
Cardiac output increase, l/min 0.26 1.3 0.44 1.5 0.05
Cardiac index increase, l/min/m2 0.14 0.7 0.27 0.9 0.05
Stroke volume increase, ml 0.32 22.1 11.07 23.31 0.05
Systemic vascular resistance, dyne/cm 1,642 524 1,581 564 0.61
Aortic valve area, cm2 1.72 0.59 1.74 0.51 0.85
Maximal gradient, mm Hg 15.4 5.8 15.3 7.5 0.93
Mean gradient, mm Hg 8.4 3.6 8.2 4.3 0.79
Values are mean SD.Abbreviations as in Table 1.in our cohort are detailed in Table 4 (and in Table 2 for
acute kidney injury).
The rates of procedure-related complications with possible
hemodynamic consequences including bleeding, vascular com-
plications, pacemaker implantation, and post-procedural infec-
tions did not differ significantly between the 2 groups (Table 2).
Figure 2. Kaplan-Meier 1-Year Survival According to BP Response
Cumulative survival after TAVI according to BP response. Abbreviations as
in Figure 1.
Table 4. SAE in Both Groups
Adverse Event
Increased BP
(n  53)
Stable BP
(n  52) p Value
In-hospital
Death* 0 (0) 4 (8) 0.056
Myocardial infarction 0 (0) 0 (0) 1.0
Stroke or TIA 2 (4) 5 (10) 0.27
Worsening heart failure 9 (17) 27 (52) 0.01
Any SAE 11 (21) 31 (60) 0.01
30 days
Death 1 (2) 4 (8) 0.20
Myocardial infarction 0 (0) 0 (0) 1.0
Stroke or TIA 2 (4) 5 (10) 0.27
Worsening heart failure 10 (19) 28 (54) 0.01
Readmission for other causes 4 (8) 9 (17) 0.14
Any SAE 16 (30) 37 (71) 0.01
12 months
Death 6 (11) 7 (13) 0.74
Myocardial infarction 0 (0) 0 (0) 1.0
Stroke or TIA 3 (6) 5 (10) 0.48
Worsening heart failure 12 (23) 31 (60) 0.01
Readmission for other causes 17 (32) 21 (40) 0.42
Any SAE 28 (53) 43 (83) 0.01
Values are n (%). *In-hospital deaths were due to: annular rupture in 1 patient; stroke in 1 patient;
and pneumonia in 2 patients.BP blood pressure; SAE serious adverse event(s); TIA transient ischemic attack.
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476The severity of post-TAVI aortic regurgitation was likewise
similar in both groups. We observed low rates of moderate
or severe aortic regurgitation as shown in Table 5.
Discussion
Hypertension following TAVI is frequent. In the study
cohort, 53 of 105 patients (51%) had increased BP that led
to intensification of antihypertensive therapy. Post-TAVI
hypertension was associated with improved LV function,
and a favorable in-hospital clinical outcome as well as at 30
days and at 12 months of follow-up. Mortality at 30 days in
Figure 3. Kaplan-Meier Event-Free Survival According to BP Response
Total serious adverse events (SAE) after 12 months of follow-up according
to the BP response after TAVI. Abbreviations as in Figure 1.
Figure 4. Kaplan-Meier Survival Free of Worsening Heart Failure Accord-
ing to BP Response
Total heart failure events after TAVI according to the BP response aftert
TAVI. Abbreviations as in Figure 1.the entire cohort was relatively low or similar to other
reported series (15–17). TAVI is a novel therapeutic option
for patients with severe and symptomatic AS that are
declined for surgery due to high surgical risk. These patients
are often old with a multitude of major comorbidities. In
our study, the average logistic EuroSCORE was 23.3 
5.1% and the prevalence of HTN was very high, approach-
ng 81%, which is similar to other reports (17,18).
Interestingly, the increase in BP after TAVI predicted a
avorable short- and mid-term clinical outcome indepen-
ent of known risk factors for surgical AVR or TAVI such
s age, LV dysfunction, ischemic heart disease, previous
TN, and chronic renal failure, which were common in our
atients (1,15,16).
Increased BP after TAVI correlated with an increase in
ardiac output, cardiac index, and stroke volume. The
elative improvement of cardiac function in patients with
ncreased BP may be the underlying mechanism for the BP
esponse as the rise in BP was not associated with better
aseline cardiac function parameters or procedural compli-
ations. Patients with increased BP were taking fewer
ntihypertensive drugs at baseline, but the level of BP
ontrol was similar before TAVI to that observed in patients
n which BP was not elevated (Table 1); thus, the difference
n the number of antihypertensives is probably not respon-
ible for the different post-procedural response.
The association between good prognosis and increased
P, a potentially harmful response, is unexpected and its
nderlying mechanism is yet to be defined. The rise in BP
ay represent myocardial contractile reserve even in pa-
ients with reduced LV function at baseline. This possibility
s supported by the fact that patients with increased BP had
significantly greater increase in both stroke volume and
ardiac output than did stable BP response patients. A
earson test for bivariate correlation between increased BP
nd an increase in cardiac output showed a significant (p 
.015), though moderate, correlation (R2  0.28) with the
ombined outcome of death or worsening heart failure. The
ise in BP may, in addition, represent a lack of adverse
vents that are associated with hypotension such as vascular
njury and bleeding. However, there were no significant
ifferences in the rates of procedural complications between
Table 5. Post-Procedural Aortic Regurgitation in Both Groups
Aortic Regurgitation Grade
Increased BP
(n  53)
Stable BP
(n  52) p Value
None or trace 8 (15) 6 (12) 0.77
Mild or mild-moderate 38 (72) 38 (73) 1.0
Moderate 7 (13) 7 (13) 1.0
Severe 0 (0) 1 (2) 0.49
Values are n (%).
BP blood pressure.he 2 groups in our study. Of note, 2 of our patients
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477developed increased BP only after pericardiocentesis for
tamponade, exemplifying that the absence of increased BP
after TAVI might be a sign of a severe complication.
HTN is generally considered a marker of poor prognosis.
Chronic HTN and accelerated HTN are well-described
contributors to cardiovascular morbidity and mortality, es-
pecially in elderly patients (19–22). Baseline HTN has been
found to be associated with worse outcomes after TAVI
(18). The better prognosis associated with an increased BP
response after TAVI persisted over 12 months of follow-up.
Longer follow-up of these patients is needed to ascertain if
increased HTN might also have negative effects on the very
elderly patients undergoing TAVI.
Arterial stiffness and the resulting loss of blood pressure
autoregulation are prevalent in elderly patients (23) and
even more common in patients with cardiovascular disease
(24,25). Reduced arterial compliance was present in our
cohort, but arterial stiffness and peripheral vascular resis-
tance cannot explain the rise in BP observed after TAVI, as
these were similar in the 2 groups. However, reduced
arterial compliance may explain the sustained nature of the
elevated BP response recorded after TAVI due to the
patients’ inability to perform adequate arterial vasodilation
after the relief of the aortic valve gradient. Of note, both
groups had well-controlled BP before TAVI. Simultane-
ously with the increase in BP after TAVI we observed a
slight reduction in diastolic pressure. This might represent
mild aortic regurgitation after valve implantation. Diastolic
BP was further decreased at day 5, probably by antihyper-
tensive treatment administered for systolic HTN.
TAVI is often performed under local anesthesia and
conscious sedation that do not afford the tight hemody-
namic control that can be achieved under general anesthesia
(26,27). We observed a BP surge immediately after valve
implantation that required prompt treatment. Treating
physicians should be aware of and alert to this response that
is more challenging when patients are only mildly sedated.
The rapid and sustained BP changes after TAVI
reported in this study for the first time are common and
should be identified and treated throughout the proce-
dure and the post-procedural phase. This is exemplified
by a patient who had an abrupt rise of systolic BP to 220
mm Hg immediately after valve deployment and conse-
quently developed severe pulmonary edema that necessi-
tated mechanical ventilation.
TAVI is a novel therapy for a challenging population of
patients. Treatment of these complex patients requires a
dedicated multidisciplinary team of interventional cardiolo-
gists, intensive care specialists, and anesthesiologists to
monitor their responses and promptly treat adverse events.
The hemodynamic responses described herein may also
bring insight to the recuperative capabilities of the myocar-
dium in patients with AS.Study limitations. The data we used for this study were
rospectively collected but the cohort size is not large and a
elatively short follow-up was used. As a result, we might
ave inherent biases between the 2 groups. In addition, the
ethod we used for calculating cardiac output is indirect
nd could possibly have led to overestimation of the differ-
nces we observed. Nevertheless, the hemodynamic changes
e noted were very significant, and we believe that these
hanges and the associated clinical outcomes are valid.
onclusions
After TAVI, about one-half of the patients have a signifi-
cant rise in systolic BP, necessitating immediate and long-
term treatment. To our knowledge, this is the first study
showing that an increase in BP after TAVI predicts a better
recovery of cardiac function and favorable short- and mid-
term clinical outcome.
Reprint requests and correspondence: Dr. Haim D. Danenberg,
Interventional Cardiology Unit, Hadassah Hebrew University
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